Browse the evidence

Key considerations when treating weight in women include the impact on sex-specific conditions and reproductive considerations of anti-obesity medications.

Practitioners should incorporate sex-specific and reproductive considerations into weight treatment plans.

Discontinuation of obesity medications often results in weight regain and reversal of health benefits.

Practitioners should monitor patients for weight regain after discontinuation and implement strategies to mitigate this.

Optimal obesity management requires a systematic assessment that extends beyond body mass index (BMI).

Clinicians should incorporate comprehensive assessments in obesity management.

Treatment modalities for obesity include lifestyle modification, pharmacotherapy, and bariatric surgery.

Clinicians should consider a range of treatment options for obesity management.

Various treatment modalities, including GLP-1 agonists and dual GLP-1/GIP agonists, are reviewed for their effects on hepatic steatosis and fibrosis.

Practitioners should consider these treatment modalities for managing MASLD.

Female sex independently predicted greater TBWL, while insulin use and higher T2D medication burden were associated with less TBWL.

Understanding these predictors can help tailor treatment strategies for weight loss.

Obesity is a significant pathogenic factor for multiple chronic conditions and ranks as the sixth leading risk factor for mortality and disability nationwide.

Healthcare practitioners should recognize obesity as a critical factor in managing chronic diseases.

GLP-1 receptor agonists and dual incretin agonists provide clinically significant benefits in weight reduction, blood pressure modulation, lipid profile improvement, and cardiovascular risk mitigation.

Practitioners can consider GLP-1 receptor agonists and dual agonists as effective options for managing weight and cardiovascular health in patients with T2DM and obesity.

Treatment would produce 75,800 quality-adjusted life-years valued at $7 billion.

Obesity treatment can significantly enhance life quality and longevity for Medicaid beneficiaries.

Dual agonists represent a transformative therapeutic class for metabolic disease management.

Clinicians should consider dual agonists as a key component in the management of metabolic diseases.

RYGB showed significantly greater weight loss than SG at both 12 months (30.3% vs. 25.4%; p < 0.001) and 24 months (26.3% vs. 21.4%; p < 0.001).

Practitioners should consider RYGB for patients seeking greater weight loss outcomes.

Both medications exhibited favorable cardiovascular profiles, though gastrointestinal adverse events constitute the predominant tolerability concern.

While both tirzepatide and retatrutide may improve cardiovascular health, practitioners should monitor for gastrointestinal side effects.

Metabolic bariatric surgery is associated with improvements in weight, AHI, upper airway collapsibility, and loop gain.

Practitioners may consider metabolic bariatric surgery as a treatment option for patients with OSA to improve various physiological traits.

82.7% of participants received no further prescriptions for antiobesity medications (AOMs) after their initial prescription.

This indicates a potential gap in ongoing obesity management for these patients.

Tirzepatide is associated with a lower risk of dementia versus SGLT2 inhibitors (HR 0.66, 95% CI 0.47-0.93, p = 0.02).

Tirzepatide may be a preferable treatment option for reducing dementia risk in type 2 diabetes patients compared to SGLT2 inhibitors.

Bariatric surgery achieves 25%–35% total body weight loss with durability extending beyond 10 years.

Bariatric surgery should be considered for long-term weight management in obese patients.

Adjuvant GLP-1RA users achieved a higher mean proportion of days covered (PDC) of 74.30% compared to 66.91% for SGA-only users.

Incorporating GLP-1RA may enhance medication adherence in patients prescribed SGAs.

Adjuvant GLP-1RA users demonstrated longer persistence of 165.6 days compared to 139.2 days for SGA-only users.

GLP-1RA may help patients stay on their SGA medications longer.

Medicaid patients using adjuvant GLP-1RA showed a PDC of 88.25% compared to 70.32% for SGA-only users.

GLP-1RA may significantly improve adherence among Medicaid patients on SGAs.

Key secondary endpoints include categorical weight-loss thresholds, changes in anthropometric and cardiometabolic measures, and comprehensive safety and tolerability assessments.

The trial will assess various health metrics alongside weight loss to evaluate overall impact.

Tirzepatide significantly improved physical function compared with placebo, with a mean difference of 2.26 points in the SF-36 physical function domain.

Practitioners can consider tirzepatide as an effective treatment to enhance physical function in adults with overweight or obesity.

The overall certainty of evidence for the effects of tirzepatide on physical function was rated as moderate due to risk of bias and inconsistency across studies.

Practitioners should be aware of the moderate certainty of evidence when considering tirzepatide for improving physical function.

Tirzepatide increases HOMA-β and decreases HOMA-IR in T2D patients.

Tirzepatide may be effective in improving insulin sensitivity and β-cell function in T2D management.

Global Guidelines for obesity management emphasize the incorporation of novel therapies and integration of standards of care with up-to-date evidence.

Clinicians should adopt these guidelines to improve obesity management globally.